An observational study in Rheumatoid Arthritis, sponsored by Kang Stem Biotech Co., Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-10.
Sponsored by Kang Stem Biotech Co., Ltd. · Observational
Among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of — 10 open to participants now, 16 under way, 2 of them phase 3. Arthritis, Rheumatoid · Korea, Republic of.
Among the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, this one is the 31st largest by planned enrollment of the 33 observational ones that give a count, is one of 6 that started in 2019, is one of 33 observational ones, reaches primary completion later than 1 of the 15 other live ones, and was the 163rd registered.
3,334 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →10 of the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of are open now. Recruiting first, the newest first:
AbbVie · Sites in Korea, Republic of, United States, Canada and 9 more countries
Ages 18+
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 18+
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Eisai Korea Inc. · Sites in Korea, Republic of
Ages 18+
Gangnam Severance Hospital · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 32 · Phase 3 74 · Phase 4 20
First in 2002; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 300 across the 155 interventional studies, 425 across the 33 observational. Of the 155 that completed or were terminated, 93 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
166 of 188 have an industry lead sponsor. The 10 most frequent:
Kang Stem Biotech Co., Ltd. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Kang Stem Biotech Co., Ltd. has 5 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
4 of the studies in Arthritis, Rheumatoid with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT07675226Oscotec Inc.Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions | 2026-12-31 |
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06246123Eisai Korea Inc.A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
A Multi-center, Open, Long-term Follow-up Study to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid arthritis: 5-year Results From the K0202 Extension Study
Moderate to Severe Rheumatoid arthritis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Not applicable(observational study)
Not applicable(observational study)
Safety Assessment
(Rate of Adverse Event, Number of Participants with Adverse Event)
Time frame: 5 years
1. Efficacy as measured by ACR(American College of Rheumatology)20,50,70 reaction rate
Time frame: 5 years
2. Efficacy as measured by EULAR (European League Against Rheumatism)reaction rate
Time frame: 5 years
change in DAS(Disease activity scores)28-ESR from baseline
DAS range is from ≥ 3.2 (inactive) , \>3.2 but ≤ 5.1(moderate), \>5.1(very active)
Time frame: 5 years
change in KHAQ(Korean Health assessment questionnaire) from baseline
KHAQ range is from 0 (clear) to 60 (severe)
Time frame: 5 years
change in CDAI (clinical disease activity index) from baseline
CDAI range is from 0 (clear) to 76 (severe)
Time frame: 5 years
change in 100mm Pain VAS(Visual analogue scale) from baseline
100mm Pain VAS range is from 0 (clear) to 100 (severe)
Time frame: 5 years
change in Modified Sharp/Van der Heijde Socre from baseline
Modified Sharp/Van der Heijde Socre range is from 0 (clear) to 448 (severe)
Time frame: 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2019 (actual). Primary completion is estimated for Aug 2025, 70 months after the start.
Of 155 industry-sponsored observational studies under Arthritis, Rheumatoid, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 116. This study's planned 70 months is above that.
Counting every sponsor, half of 391 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kang Stem Biotech Co., Ltd.